- Home
- OPK vs CRGX Comparison
OPK vs CRGX Comparison
Compare OPK & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPK
- CRGX
- Stock Information
- Founded
- OPK 2007
- CRGX 2021
- Country
- OPK United States
- CRGX United States
- Employees
- OPK N/A
- CRGX N/A
- Industry
- OPK Biotechnology: Pharmaceutical Preparations
- CRGX
- Sector
- OPK Health Care
- CRGX
- Exchange
- OPK Nasdaq
- CRGX Nasdaq
- Market Cap
- OPK 1.1B
- CRGX 633.3M
- IPO Year
- OPK 1995
- CRGX 2023
- Fundamental
- Price
- OPK $1.45
- CRGX $15.05
- Analyst Decision
- OPK Strong Buy
- CRGX Strong Buy
- Analyst Count
- OPK 3
- CRGX 6
- Target Price
- OPK $2.75
- CRGX $31.80
- AVG Volume (30 Days)
- OPK 3.3M
- CRGX 285.4K
- Earning Date
- OPK 02-25-2025
- CRGX 11-12-2024
- Dividend Yield
- OPK N/A
- CRGX N/A
- EPS Growth
- OPK N/A
- CRGX N/A
- EPS
- OPK N/A
- CRGX N/A
- Revenue
- OPK $711,408,000.00
- CRGX N/A
- Revenue This Year
- OPK N/A
- CRGX N/A
- Revenue Next Year
- OPK $0.00
- CRGX N/A
- P/E Ratio
- OPK N/A
- CRGX N/A
- Revenue Growth
- OPK N/A
- CRGX N/A
- 52 Week Low
- OPK $0.85
- CRGX $12.17
- 52 Week High
- OPK $1.76
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- OPK 34.57
- CRGX 46.65
- Support Level
- OPK $1.43
- CRGX $13.10
- Resistance Level
- OPK $1.54
- CRGX $14.94
- Average True Range (ATR)
- OPK 0.07
- CRGX 1.40
- MACD
- OPK -0.01
- CRGX 0.14
- Stochastic Oscillator
- OPK 6.06
- CRGX 59.63
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.